Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6219680 | 0.98 | KMT2A (0.53) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL8120684 | 0.84 | KMT2A (0.54) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2314704 | 0.82 | KMT2A (0.53) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL19036932 | 0.82 | KMT2A (0.38) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL13394254 | 0.79 | KMT2A (0.70) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL19036931 | 0.78 | CYP2D6 (0.40) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL1723901 | 0.78 | CYP2D6 (0.40) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| Bromide SCHEMBL1645919 | 0.78 | KMT2A (0.73) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| Bromide SCHEMBL1646164 | 0.78 | KMT2A (0.52) | KMT2ASMN1; SMN2POLBNPC1RAB9A | |
| Bromide SCHEMBL8652311 | 0.78 | KMT2A (0.60) | KMT2ASMN1; SMN2POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233801-B1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | OREAL (FR) | 2022-06-08 | — | — | EP | disclosed |
| CN-106999394-B | Use, composition and implementation method of specific pyridinium salt for treating keratin materials | 欧莱雅 | 2021-09-24 | — | — | CN | disclosed |
| US-10765615-B2 | Use of particular pyridinium salts for the treatment of keratin substances, compositions and implementation methods | L'OREAL (FR) | 2020-09-08 | — | — | US | disclosed |
| US-20170340543-A1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | L'OREAL (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170340543-A1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | L'OREAL (FR) | 2017-11-30 | — | — | US | disclosed |
| EP-3233801-A1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | L'OREAL (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097413-A1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | L'OREAL (FR) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097413-A1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | L'OREAL (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340543-A1 | USE OF PARTICULAR PYRIDINIUM SALTS FOR THE TREATMENT OF KERATIN SUBSTANCES, COMPOSITIONS AND IMPLEMENTATION METHODS | KRT18, PLPBP, PNPO | KMT2A 1799/4885SMN1; SMN2 4722/4885POLB 467/4885 |
| US-10765615-B2 | Use of particular pyridinium salts for the treatment of keratin substances, compositions and implementation methods | KRT18, PLPBP, PNPO | KMT2A 1799/4885SMN1; SMN2 4722/4885POLB 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.